WuXi Biologics Honored with Three IMAPAC Awards, Including “CDMO of the Year”

SINGAPORE, Sept. 11, 2025 – WuXi Biologics (2269.HK), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has secured a trio of accolades at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025, cementing its position as a leader in the biopharmaceutical industry. Hosted by IMAPAC, the awards recognized WuXi Biologics as “CDMO of the Year – Asia Pacific,” bestowed the “Best Biologics CDMO Award: Bioprocessing,” and hailed the company as the “Best Biologics CDMO in Greater China Region.” This isn’t WuXi Biologics’ first rodeo; since 2017, the company has consistently garnered recognition across various categories at IMAPAC’s events.

The APBCEA program aims to spotlight CDMOs that are instrumental in accelerating biologics innovation across the Asia Pacific region. The awards criteria focus on excellence in biomanufacturing, pioneering R&D initiatives, impactful technological innovations, and strategic partnerships that propel the development and commercialization of next-generation biologic therapies. This year’s recognition underscores WuXi Biologics’ strategic focus on building a robust and globally competitive platform.

WuXi Biologics has significantly invested in its integrated technology platforms to streamline the discovery, development, and manufacturing of biologics. The company’s portfolio encompasses a substantial number of complex biologics, boasting a total of 864 integrated projects, including 168 bispecific and multispecific antibodies, and 225 Antibody-Drug Conjugates (ADCs). Notably, WuXi Biologics has compressed the development timeline for monoclonal antibody projects from DNA to Investigational New Drug (IND) application to just 6 months, a development cycle that reflects not only efficiencies, but also the company’s advanced technological capabilities. This rapid development pace is critical in the fast-moving biotech landscape. Key to these achievements is the company’s commitment to stringent quality systems, exemplified by a 100% success rate in Pre-License Inspections (PLI) and the successful completion of 44 inspections by stringent global regulatory bodies, including 22 by the FDA and EMA. These milestones highlight the company’s deep understanding of regulatory pathways and quality control. Leveraging these advanced technologies, world-class quality systems, a broad global manufacturing footprint, and a proven track record of success, WuXi Biologics provides end-to-end solutions for over 1000 clients worldwide, helping them to accelerate their biologics from the lab to the market. This end-to-end service has positioned WuXi Biologics as a crucial partner for companies of all sizes, from small biotech startups to established pharmaceutical giants.

Dr. Chris Chen, CEO of WuXi Biologics, stated, “These multiple awards from IMAPAC are a significant validation of our efforts and the value we deliver to our clients and the industry. Our unwavering commitment to excellence, world-class quality standards, a visionary leadership team, and a dedicated global team allows us to empower our partners to accelerate the delivery of innovative therapies to patients around the world.” This commitment to quality and innovation is a driving force behind the company’s growth and success.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com